Xeris Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xeris Biopharma Holdings, Inc. (XERS) on September 9, 2026. The filing serves as a Regulation FD disclosure regarding an upcoming investor webinar and the release of a press announcement concerning the Company's XP-8121 Program Overview.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate event and does not contain financial statements or performance data.
Material Changes
No material financial changes versus prior periods are reported in this filing. The primary event is the scheduled dissemination of information regarding the XP-8121 clinical program.
Guidance, Outlook, and Management Commentary
- Event: The Company hosted an XP-8121 Program Overview webinar on September 9, 2026.
- Disclosure: A slide presentation (Exhibit 99.1) and a press release (Exhibit 99.2) detailing the program overview were furnished with this report.
- Legal Status: The information in Item 7.01 and its exhibits is furnished, not filed, for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Investor Presentation) for specific data points regarding the XP-8121 program.
- Read Exhibit 99.2 (Press Release) for the official public announcement details.
- Verify the Company's website (www.xerispharma.com) under the "Investors" tab for the accessible copy of the presentation, noting that website content is not part of this filing.
- Confirm that no financial metrics were included in this specific 8-K filing.